About Relay Therapeutics
Relay Therapeutics is a company based in Cambridge (United States) founded in 2016 by Dorothee Kern and David E Shaw. Relay Therapeutics has raised $520 million across 4 funding rounds from investors including ARE, SoftBank Vision Fund and Perceptive Advisors. The company has 261 employees as of December 31, 2024. Relay Therapeutics has completed 1 acquisition, including ZebiAI. Relay Therapeutics offers products and services including Dynamo Platform and Therapeutic Pipeline. Relay Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Cambridge, United States
- Employees 261 as on 31 Dec, 2024
- Founders Dorothee Kern, David E Shaw
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Relay Therapeutics, Inc.
-
Annual Revenue
$10.01 M (USD)-60.83as on Dec 31, 2024
-
Net Profit
-$337.71 M (USD)1.25as on Dec 31, 2024
-
EBITDA
-$380.21 M (USD)-1.62as on Dec 31, 2024
-
Total Equity Funding
$520 M (USD)
in 4 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Jan 10, 2024
-
Investors
ARE
& 12 more
-
Employee Count
261
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Relay Therapeutics
Relay Therapeutics is a publicly listed company on the NASDAQ with ticker symbol RLAY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Relay Therapeutics
Relay Therapeutics offers a comprehensive portfolio of products and services, including Dynamo Platform and Therapeutic Pipeline.
Enables visualization of protein motion for developing new therapeutics.
Advances candidates for oncology and genetic disease treatments.
People of Relay Therapeutics
Unlock access to complete
Leadership Team
21 people
Finance and Accounting
11 people
Product Management Team
10 people
Operations Team
6 people
Senior Team
4 people
Legal and Compliance
3 people
Software Development Team
2 people
Data Analysis and Operations Team
2 people
Unlock access to complete
Funding Insights of Relay Therapeutics
Relay Therapeutics has successfully raised a total of $520M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Relay Therapeutics
Relay Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, SoftBank Vision Fund and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked |
Investor details for Relay Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Relay Therapeutics
Relay Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ZebiAI.
Investment portfolio details for Relay Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI solutions for small molecule drug discovery are provided.
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Relay Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Relay Therapeutics
Detailed financials for Relay Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Relay Therapeutics Comparisons
Peer comparison for Relay Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Relay Therapeutics
Relay Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Relay Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Relay Therapeutics
Complete news archive for Relay Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Relay Therapeutics
Relay Therapeutics was founded in 2016.
Relay Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Sanjiv Patel is the current CEO of Relay Therapeutics.
Relay Therapeutics is a funded company, having raised a total of $520M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Relay Therapeutics is 261.
Annual revenue of Relay Therapeutics is $10.01M as on Dec 31, 2024.
Relay Therapeutics was founded in 2016 and is based in Cambridge, United States. Operations center on a drug discovery engine that generates 3D visualizations of protein mobility to analyze protein functions through motion. Ligand-binding pockets in proteins are examined, and interactions between ligands and proteins are identified. Initial efforts are directed toward oncology therapeutics.
Relay Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Relay Therapeutics offers Dynamo Platform and Therapeutic Pipeline.
Yes, Relay Therapeutics is publicly traded on NASDAQ under the ticker symbol RLAY.
Relay Therapeutics has made 1 acquisition, including ZebiAI.
Relay Therapeutics has 13 investors. Key investors include ARE, SoftBank Vision Fund, Perceptive Advisors, Google Ventures, and Casdin Capital.
The ticker symbol of Relay Therapeutics is RLAY on NASDAQ.